SYMPAZAN: payments to doctors
Payments that named SYMPAZAN as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $940K
- Providers
- 2,066
- Transactions
- 8,465
- Average per transaction
- $111
The per-transaction average — $111 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 2,066 providers the average total is $455, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Aquestive Therapeutics, Inc. | $795,727 | 84.6% |
| Otter Pharmaceuticals, LLC | $141,447 | 15.0% |
| Assertio Therapeutics, Inc. | $3,080 | 0.3% |